Literature DB >> 16484654

Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy.

C R Baumann1, R Khatami, E Werth, C L Bassetti.   

Abstract

Cerebrospinal fluid (CSF) hypocretin-1 deficiency is associated with definite ("clear cut") cataplexy in patients with narcolepsy. The relationship between CSF hypocretin-1 levels and other narcoleptic symptoms (including excessive daytime sleepiness, EDS) is not properly understood. In a consecutive series of 18 subjects with narcolepsy and definite cataplexy, patients with undetectable CSF hypocretin-1 (n = 12) were found to have significantly lower mean sleep latencies (p = 0.045) and a higher frequency of sleep onset REM periods (SOREMPs, p = 0.025) on multiple sleep latency test than patients (n = 6) with detectable levels. Conversely, Epworth sleepiness scale scores, the frequency of hallucinations/sleep paralysis, and the frequency and severity of cataplexy were similar in both groups. These results suggest that hypocretin deficiency identifies a homogenous group of patients with narcolepsy characterised by the presence of definite cataplexy, severe EDS, and frequent SOREMPs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16484654      PMCID: PMC2077721          DOI: 10.1136/jnnp.2005.067207

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  11 in total

1.  Idiopathic hypersomnia. A series of 42 patients.

Authors:  C Bassetti; M S Aldrich
Journal:  Brain       Date:  1997-08       Impact factor: 13.501

2.  Validation of a cataplexy questionnaire in 983 sleep-disorders patients.

Authors:  S Anic-Labat; C Guilleminault; H C Kraemer; J Meehan; J Arrigoni; E Mignot
Journal:  Sleep       Date:  1999-02-01       Impact factor: 5.849

3.  Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy.

Authors:  S Nishino; B Ripley; S Overeem; S Nevsimalova; G J Lammers; J Vankova; M Okun; W Rogers; S Brooks; E Mignot
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

4.  The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.

Authors:  Emmanuel Mignot; Gert Jan Lammers; Beth Ripley; Michele Okun; Sonia Nevsimalova; Sebastiaan Overeem; Jitka Vankova; Jed Black; John Harsh; Claudio Bassetti; Harald Schrader; Seiji Nishino
Journal:  Arch Neurol       Date:  2002-10

5.  HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients.

Authors:  E Mignot; R Hayduk; J Black; F C Grumet; C Guilleminault
Journal:  Sleep       Date:  1997-11       Impact factor: 5.849

Review 6.  Hypocretins (orexins): clinical impact of the discovery of a neurotransmitter.

Authors:  Christian R Baumann; Claudio L Bassetti
Journal:  Sleep Med Rev       Date:  2005-08       Impact factor: 11.609

7.  CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia.

Authors:  Takashi Kanbayashi; Yuichi Inoue; Shigeru Chiba; Rika Aizawa; Yasushi Saito; Haruko Tsukamoto; Yukiharu Fujii; Seiji Nishino; Tetsuo Shimizu
Journal:  J Sleep Res       Date:  2002-03       Impact factor: 3.981

8.  The clinical spectrum of narcolepsy with cataplexy: a reappraisal.

Authors:  Christian Sturzenegger; Claudio L Bassetti
Journal:  J Sleep Res       Date:  2004-12       Impact factor: 3.981

9.  Monozygotic twins concordant for narcolepsy-cataplexy without any detectable abnormality in the hypocretin (orexin) pathway.

Authors:  Ramin Khatami; Stéphanie Maret; Esther Werth; Julia Rétey; Dagmar Schmid; Friedrich Maly; Mehdi Tafti; Claudio L Bassetti
Journal:  Lancet       Date:  2004-04-10       Impact factor: 79.321

10.  CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions.

Authors:  Y Dauvilliers; C R Baumann; B Carlander; M Bischof; T Blatter; M Lecendreux; F Maly; A Besset; J Touchon; M Billiard; M Tafti; C L Bassetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-12       Impact factor: 10.154

View more
  7 in total

1.  Dietary therapy restores glutamatergic input to orexin/hypocretin neurons after traumatic brain injury in mice.

Authors:  Jonathan E Elliott; Samuel E De Luche; Madeline J Churchill; Cindy Moore; Akiva S Cohen; Charles K Meshul; Miranda M Lim
Journal:  Sleep       Date:  2018-03-01       Impact factor: 5.849

2.  Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population.

Authors:  Stine Knudsen; Poul J Jennum; Jørgen Alving; Søren Paludan Sheikh; Steen Gammeltoft
Journal:  Sleep       Date:  2010-02       Impact factor: 5.849

3.  Normal cerebrospinal fluid histamine and tele-methylhistamine levels in hypersomnia conditions.

Authors:  Yves Dauvilliers; Nathalie Delallée; Isabelle Jaussent; Sabine Scholz; Sophie Bayard; Mickael Croyal; Jean-Charles Schwartz; Philippe Robert
Journal:  Sleep       Date:  2012-10-01       Impact factor: 5.849

4.  The economic consequences of narcolepsy.

Authors:  Poul Jennum; Stine Knudsen; Jakob Kjellberg
Journal:  J Clin Sleep Med       Date:  2009-06-15       Impact factor: 4.062

Review 5.  Neuroimaging findings in narcolepsy with cataplexy.

Authors:  Thien Thanh Dang-Vu
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 5.081

6.  Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency.

Authors:  Olivier Andlauer; Hyatt Moore; Laura Jouhier; Christopher Drake; Paul E Peppard; Fang Han; Seung-Chul Hong; Francesca Poli; Giuseppe Plazzi; Ruth O'Hara; Emmanuel Haffen; Thomas Roth; Terry Young; Emmanuel Mignot
Journal:  JAMA Neurol       Date:  2013-07       Impact factor: 18.302

7.  Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy.

Authors:  Olivier Andlauer; Hyatt Moore; Seung-Chul Hong; Yves Dauvilliers; Takashi Kanbayashi; Seiji Nishino; Fang Han; Michael H Silber; Tom Rico; Mali Einen; Birgitte R Kornum; Poul Jennum; Stine Knudsen; Sona Nevsimalova; Francesca Poli; Giuseppe Plazzi; Emmanuel Mignot
Journal:  Sleep       Date:  2012-09-01       Impact factor: 5.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.